In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Poster session 2: Cardiovascular prevention outcomes I
Session

Event : ESC Congress 2016

Topic : Other

  • Session type : Poster Session
  • Date : 28 August 2016
  • Time : 08:30 - 12:30

20 presentations in this session

Evolution of European Society of Cardiology Guidelines since 2000: a systematic appraisal

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : C Badu-Boateng (London,GB)

The treatment benefit of the ACE-inhibitor perindopril on top of beta-blocker therapy in patients with vascular disease

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : JJ Brugts (Rotterdam,NL)

Healthcare use in peripheral arterial disease without history of stroke/TIA in a large health organization

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : L Bash (Whitehouse Station,US)

Efficacy of evolocumab in patients across ESC/EAS CV risk subgroups

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : E Stroes (Amsterdam,NL)

Comparative renal safety of rosuvastatin versus other statins in patients with very high cardiovascular risk

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : F Colivicchi (Rome,IT)

Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolaemia

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : GK Hovingh (Amsterdam,NL)

Pharmacokinetics and pharmacodynamics of evolocumab in patients with renal impairment

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : E Lee (Thousand Oaks,US)

Comparison of efficacy and safety of rosuvastatin 15 mg vs. 10 mg: subanalysis of the ROSU-PATH trial

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : M Cevc (Ljubljana,SI)

LDL extracellular vesicle coagulation protein levels change after initiation of statin therapy in healthy individuals

Event : ESC Congress 2016

  • Session : Cardiovascular prevention outcomes I
  • Speaker : YN Zhang (Singapore,SG)

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now
logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are